ReviewRespiratory medicine2020
Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19.
Review in Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.Journal of aerosol medicine and pulmonary drug delivery · 2020Guideline
- Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants.Molecular therapy. Methods & clinical development · 2025Article
- Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens.Viruses · 2025Review
- The influence of novel coronavirus pneumonia on chronic disease management of asthma-a narrative review.Journal of thoracic disease · 2024Review
- Nebuliser therapy in critical care: The past, present and future.Journal of the Intensive Care Society · 2024Review
- Article
- Influence of Aerosol Mask Design on Fugitive Aerosol Concentrations During Nebulization.Respiratory care · 2023Article
- Genetically Engineered Cellular Nanovesicle as Targeted DNase I Delivery System for the Clearance of Neutrophil Extracellular Traps in Acute Lung Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections.Pharmaceutical research · 2023Review
- A review on indoor airborne transmission of COVID-19- modelling and mitigation approaches.Journal of building engineering · 2023Review
- Estimated cost-savings from optimizing use of inhaled medications for inpatients with obstructive lung disease.The Journal of asthma : official journal of the Association for the Care of Asthma · 2023Article
- Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China.Emerging infectious diseases · 2022Article
- Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.Journal of pharmaceutical sciences · 2022Review
- Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.International journal of pharmaceutics · 2022Review
- Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition.NPJ digital medicine · 2022Article
- Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.Pharmaceutics · 2022Article
- Celecoxib Microparticles for Inhalation in COVID-19-Related Acute Respiratory Distress Syndrome.Pharmaceutics · 2022Article
- Pulmonary Procedures During the COVID-19 Pandemic: A Work Group Report of the AAAAI Asthma Diagnosis and Treatment (ADT) Interest Section.The journal of allergy and clinical immunology. In practice · 2022Article
- Primary Care Management of Asthma Exacerbations or Attacks: Impact of the COVID-19 Pandemic.Advances in therapy · 2022Article
- Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review.Pulmonary therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19, the disease caused by a novel coronavirus and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe. It has caused outbreaks of illness due to person-to-person transmission of the virus mainly via close contacts and droplets produced by an infected person's cough or sneeze. Exhaled droplets from infected patients with COVID-19 can be inhaled into the lungs and leads to respiratory illness such as pneumonia and acute respiratory distress syndrome. Although aerosol therapy is a mainstay procedure used to treat pulmonary diseases at home and healthcare settings, it has a potential for fugitive emissions during therapy due to the generation of aerosols and droplets as a source of respiratory pathogens. Delivering aerosolized medications to patients with COVID-19 can aggravate the spread of the novel coronavirus. This has been a real concern for caregivers and healthcare professionals who are susceptible to unintended inhalation of fugitive emissions during therapy. Due to a scarcity of information in this area of clinical practice, the purpose of this paper is to explain how to deliver aerosolized medications to mild-, sub-intensive, and intensive-care patients with COVID-19 and how to protect staff from exposure to exhaled droplets during aerosol therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.